All three major PBMs agree to cover Foundayo

Eli Lilly said on May 28, 2026 that all three of the nation's largest pharmacy benefit managers will now cover its full obesity drug lineup, after CVS Caremark agreed to add the oral GLP-1 pill Foundayo (orforglipron) to its commercial template formulary on June 1, 2026 and to bring back Zepbound (tirzepatide) by October 1, 2026 ^[1].

CVS Health confirmed the changes the same day. The company said it will remove the "new-to-market block" on Foundayo effective June 1, 2026, "where approved for coverage by plans," and will add Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026 ^[2]. CVS Caremark is one of the largest PBMs in the country, with roughly 88 million plan members as of March 31, 2026 ^[2].

What the coverage actually includes

Lilly said eligible patients with commercial insurance may pay as little as $25 a month for either medicine, though the announcement attaches conditions in a footnote that the release does not spell out ^[1]. Lilly also said Medicare Part D beneficiaries may be eligible to pay $50 per month for its obesity medicines beginning July 1 through a program it calls the Medicare GLP-1 Bridge ^[1]. Details of how that program works are not described in the sources.

An important limit: CVS Caremark's template formularies are a starting list, not a guarantee. The company said plan sponsors — employers, health plans, unions and government entities — "retain discretion to customize coverage for their members" ^[2]. In other words, whether an individual worker's plan covers weight-loss drugs at all still depends on that employer's choices.

Lilly said coverage for people already taking Zepbound "continues uninterrupted," with access broadening across template plans by October 1 ^[1].

The money behind the deal

CVS framed the change as the result of price negotiations rather than a shift in clinical thinking. "We acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access," said Ed DeVaney, president of CVS Caremark ^[2]. The company said it expects the changes to "drive increased savings in the weight management category" and noted that broad demand for high-priced medicines "creates a level of financial strain that is difficult to absorb at scale," which has pushed many customers to limit coverage ^[2].

Lilly's Ilya Yuffa, executive vice president and president of Lilly USA, said in the release that "for too long, effective obesity treatment has been out of reach for the people who need it" ^[1].

Neither company named the other two large PBMs in these announcements, and the specific terms, rebates or prices negotiated were not disclosed in either source.

Why it matters for patients

For people with commercial insurance through a CVS Caremark-administered plan, the practical effect is that two Lilly obesity drugs move from blocked or excluded to potentially covered — but on different dates, and only if the employer or plan sponsor buys into weight-management coverage. Foundayo's block lifts June 1, 2026; Zepbound returns as a preferred option October 1, 2026 ^[2].

The two drugs are not interchangeable. Foundayo is a once-daily oral GLP-1 pill that Lilly says can be taken any time of day without restrictions on food or water ^[1]. In the ATTAIN-1 trial, people on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4% of body weight, over 72 weeks, versus 2.2 pounds (0.9%) on placebo; counting everyone regardless of whether they finished on the drug, the average was 25 pounds (11.1%) versus 5.3 pounds (2.1%) ^[1]. Zepbound is an injection that also targets the GIP receptor; in SURMOUNT-1, average weight loss over 72 weeks was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, compared with 3.1% on placebo ^[1]. These come from separate trials and were not compared head-to-head.

Both carry a boxed warning that they may cause thyroid tumors, including thyroid cancer, and Zepbound's label lists risks including pancreatitis, gallbladder problems, dehydration and kidney problems, and low blood sugar when combined with insulin or sulfonylureas ^[1].

What happens next

• June 1, 2026: Foundayo becomes available on CVS Caremark commercial templates where plans have approved coverage ^[2].
• July 1, 2026: Lilly's stated start date for $50-a-month pricing for eligible Medicare Part D beneficiaries ^[1].
• October 1, 2026: Zepbound returns as an additional preferred option on CVS Caremark commercial formularies ^[2].

CVS said it will do proactive outreach to customers, providers and members about the transition ^[2]. Lilly directs people to its coverage-check tools, noting that coverage information changes regularly ^[1].